No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
CDXC241220P7500
- 2.05
- +0.05+2.50%
15min DelayClose Dec 20 16:00 ET
2.05High2.05Low
2.05Open2.00Pre Close1 Volume335 Open Interest7.50Strike Price205.00Turnover0.00%IV0.73%PremiumDec 20, 2024Expiry Date2.01Intrinsic Value100Multiplier-1DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.71Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
ChromaDex Corporation's (NASDAQ:CDXC) 28% Cheaper Price Remains In Tune With Revenues
Even Though ChromaDex (NASDAQ:CDXC) Has Lost US$73m Market Cap in Last 7 Days, Shareholders Are Still up 389% Over 1 Year
Analysts Offer Insights on Healthcare Companies: Chromadex (CDXC) and Sagimet Biosciences, Inc. Class A (SGMT)
Ladenburg Thalmann Maintains ChromaDex(CDXC.US) With Buy Rating, Raises Target Price to $6.8
Roth MKM Maintains ChromaDex(CDXC.US) With Buy Rating, Maintains Target Price $8
An Intrinsic Calculation For ChromaDex Corporation (NASDAQ:CDXC) Suggests It's 21% Undervalued